Elevated Blood Urea Nitrogen is associated with Recurrence of post-operative Chronic Subdural Hematoma

Ning Wang  
Wenzhou medical university  
https://orcid.org/0000-0002-5206-1636

Jiangnan Hu  
University of North Texas Health Science Center

Anthony Oppong-Gyebi  
University of North Texas Health Science Center

Xuanhao Zhu  
Wenzhou Medical University

Yihao Li  
Wenzhou Medical University

Jianjing Yang  
Wenzhou Medical University First Affiliated Hospital

Linhui Ruan  
Wenzhou Medical University First Affiliated Hospital

Qichuan Zhuge  
Wenzhou Medical University First Affiliated Hospital

Sheng Ye (✉️ yesheng342@163.com)  
https://orcid.org/0000-0003-1281-1735

Research article

Keywords: Chronic subdural hematoma, Blood urea nitrogen (BUN), Recurrence rate

DOI: https://doi.org/10.21203/rs.3.rs-17614/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Chronic subdural hematoma (CSDH) is fundamentally treatable with about a 2-31% recurrence rate. Recently, there has been renewed interest in the association between Blood Urea Nitrogen (BUN) and intracranial lesion. Therefore, this paper attempts to show the relationship between BUN and CSDH recurrence.

Methods: A total of 653 CSDH cases with Burr-hole Irrigation (BHI) were enrolled from December 2014 to April 2019. The analyzed parameters included age, gender, comorbidities, laboratory investigations, medication use and hematoma location. The cases were divided into recurrence and non-recurrence groups while postoperative BUN concentration was further separated into quartiles (Q1 \leq 4.0 \text{ mmol/L}, 4.0 < Q2 \leq 4.9 \text{ mmol/L}, 4.9 < Q3 \leq 6.4 \text{ mmol/L}, Q4 > 6.4 \text{ mmol/L}). Restricted cubic spline regressions and logistic regression models were performed to estimate the effect of BUN on CSDH recurrence.

Results: CSDH recurrence was observed in 96 (14.7%) cases. Significant distinctions were found between recurrence and non-recurrence groups in postoperative BUN quartiles of cases ($P=0.003$). After adjusting for the potential confounders, the odds ratio of recurrence was 3.069 (95%CI =1.488–6.330, $p = 0.002$) for the highest quartile of BUN compared with the lowest quartile. In multiple-adjusted spline regression, a high BUN level visually showed a significantly high OR value of recurrence risk.

Conclusions: Elevated BUN at post-operation is significantly associated with the recurrence of CSDH, and it is indicated that high levels of serum BUN after evacuation may serve as a risk factor for CSDH recurrence.

Background

Chronic subdural hematoma (CSDH) is a frequently encountered neurosurgical disorder that is common among the aged. The incidence of CSDH is estimated to be 8.2-17.6 per 100,000 persons per year which increases along with increasing age[1-3]. Burr-hole irrigation (BHI) is most widely used to treat CSDH with a relatively good outcome, but about 2-31% of patients relapse after the initial operation[1].

Factors found to influence CSDH recurrence have been reported in several studies, including age, Glasgow coma score (GCS), antiplatelet or anticoagulant agents, bilateral hematomas, postoperative pneumocephalus, and other certain related computed tomography (CT) findings[4-7]. However, the findings of the connection between laboratory investigation and CSDH recurrence are still scarce.

Blood urea nitrogen (BUN) concentration is an easily overlooked investigation. Interestingly, there is a growing amount of literature that recognizes high BUN/creatinine(Cr) as an independent risk factor of poor outcomes in acute ischemic stroke (AIS) patients[8-10]. Furthermore, elevated BUN concentration was revealed to increase in-hospital mortality in AIS patients[11]. These studies indicated that BUN was associated with intracranial disorders. But very little attention has been paid to the relationship between BUN and CSDH recurrence so far.
In this paper, variables associated with CSDH recurrence were investigated, focusing on the postoperative BUN concentrations of patients with CSDH who underwent evacuation at a single facility from 2014 to 2019. This research aimed to explore the relationship between serum BUN levels and CSDH recurrence to provide a new orientation to study the pathophysiology of CSDH.

**Methods**

**Patients and parameters**

This study enrolled admitted patients with the diagnosis of CSDH at the First Affiliated Hospital of Wenzhou Medical University, Zhejiang province, China, between December 2014 and April 2019. Patients with CSDH were diagnosed by head magnetic resonance imaging (MRI) and CT. The following exclusive criteria were used: (1) without surgical treatment; (2) younger than 18 years old; (3) severe epilepsy; (4) severe renal or blood diseases; (5) hematoma organized or bad operation result; (6) craniotomy or evacuated by other departments; (7) lack of laboratory investigation; (8) hospital mortality. Patient with two operations was defined as two cases.

The following clinical characteristics were analyzed: age, gender, demographic parameters, comorbidities, postoperative laboratory investigations, postoperative medication use, location of hematoma, and preoperative BUN level. Glasgow outcome scale (GOS) at discharge was performed to evaluate the neurologic function of patients.

**Surgery procedure and follow-up**

All patients underwent BHI with general anesthesia. After burr-hole exposure, dura incision and irrigation, we used closed system drainage with a subdural catheter connected to a vacuum plastic bag. Most catheters were withdrawn within 72h after the operation. Head CT was performed within the first 48 hours and on day 6 or 7 postoperatively. For good measure, patients were followed up with head CT at 3 months at the outpatient service.

**Definition of recurrence and grouping**

CSDH recurrence was evaluated by radiological criteria, which included an increased volume of the subdural collection and brain compression on either side within 3 months compared with those first measured after surgery through CT scans, and clinical criteria in which preoperative symptoms and signs abided or recurred (Figure 2). The classification of recurrence was determined by two experienced neurosurgeons who were blinded to the study.

The cases were first divided into 2 groups according to recurrence and non-recurrence to investigate the risk factors for CSDH recurrence. To identify the specific effect of postoperative BUN, it was further divided into quartiles to explore the different influences on the CSDH recurrence in each category. The local ethics committee ruled that no formal ethics approval was required in this particular study.
Statistical analysis

Data for continuous variables were shown as mean ± standard deviation or medians and interquartile range. To verify whether the data follows a normal distribution or not, Kolmogorov-Smirnov test was performed. Categorical variables were shown as relative frequencies and percentages. Normally distributed variables were compared by Student’s t-test, whereas the Mann–Whitney U test was used for the asymmetrically distributed continuous variables. Chi-squared ($\chi^2$) test was used to compare categorical variables. Statistical comparisons among BUN concentrations stratification were estimated by one-way analysis of variance (ANOVA) or Kruskal–Wallis test for continuous variables, and Pearson's chi-square test for categorical variables where appropriate. Wilcoxon signed-rank test was performed to compare the difference between pre and post-operative BUN levels. Odds ratio (OR) and 95% confidence interval (CI) for recurrence risk were calculated by performing multivariate-adjusted binary logistic regression. Restricted cubic spline regressions model was built to examine the linear relation between serum BUN concentration and the risk of recurrence. In this study, a two-tailed $p$-value less than 0.05 ($P < 0.05$) was considered as statistical significance. All statistical analyses were done using SPSS (version 23.0, IBM Corp.) and STATA software (version 12, StataCorp LP) was employed to analyze the restricted cubic spline regressions.

Results

Baseline characteristics of all cases in the recurrence group and Non-recurrence group

A total of 653 CSDH cases were enrolled in this study (Figure 1). This study group included 561 male cases (85.9%) and 92 female cases (14.1%). Patient’s age ranged from 21 to 100 years with a median of 72 years (interquartile range 64 to 80 years). (Table 1). 8 patients with hospitalized mortality were excluded and there was no mortality upon follow-up in this study.

Table 1
Clinical and Demographic Characteristics of Patients with CSDH.
| Variables                                      | All patients (N=653) | Recurrence n=96 | Non-Recurrence n=557 | P-value |
|------------------------------------------------|---------------------|-----------------|----------------------|---------|
| **Postoperative BUN (mmol/L)**                 | 4.9 (4.6, 4.4)      | 5.9 (4.4, 6.9)  | 4.9 (3.9, 6.3)       | <0.001  |
| **Demographic parameters**                     |                     |                 |                      |         |
| Age (years)                                    | 72 (64, 80)         | 75 (69, 82)     | 71 (63, 80)          | 0.012   |
| Gender                                         |                     |                 |                      | 0.263   |
| Male, n (%)                                    | 561 (85.9%)         | 86 (89.6%)      | 475 (85.3%)          |         |
| Female, n (%)                                  | 92 (14.1%)          | 10 (10.4%)      | 82 (14.7%)           |         |
| Current drinking, n (%)                        | 234 (35.8%)         | 34 (35.4%)      | 200 (35.9%)          | 0.926   |
| Current smoking, n (%)                         | 237 (36.3%)         | 33 (34.4%)      | 204 (36.6%)          | 0.672   |
| Baseline SBP (mmHg)                            | 138 (126, 153)      | 135 (124, 151)  | 140 (127, 153)       | 0.122   |
| Baseline DBP (mmHg)                            | 79 (71, 87)         | 77 (71, 84)     | 79 (71, 87)          | 0.091   |
| **Laboratory investigation**                   |                     |                 |                      |         |
| Blood glucose (mmol/L)                         | 5.5 (4.7, 6.6)      | 5.7 (5.6, 7)    | 5.4 (4.7, 6.6)       | 0.265   |
| Cr (μmol/L)                                    | 67 (58, 77)         | 68 (60, 80)     | 66 (57, 77)          | 0.097   |
| Leukocyte (X10^9/L)                            | 6.94 (5.81, 8.43)   | 6.51 (5.52, 7.55)| 7.01 (5.85, 8.62)   | 0.010   |
| Neutrophil (X10^9/L)                           | 4.62 (3.68, 6.15)   | 4.30 (3.51, 5.31)| 4.70 (3.71, 6.26)   | 0.012   |
| Lymphocyte (X10^9/L)                           | 1.46 (1.10, 1.81)   | 1.46 (1.17, 1.83)| 1.47 (1.1, 1.81)    | 0.650   |
| Erythrocyte (X10^12/L)                         | 4.23 ± 0.51         | 4.19 ± 0.52     | 4.24 ± 0.51          | 0.379   |
| Hemoglobin (g/L)                               | 132 (120, 142)      | 132 (119, 142)  | 132 (119, 140)       | 0.442   |
| Platelet (X10^9/L)                             | 211 (172, 249)      | 194 (164, 239)  | 213 (175, 251)       | 0.010   |
| Prothrombin Time(s)                            | 13.3 (12.8, 13.9)   | 13.4 (12.8, 14.0)| 13.3 (12.8, 13.9)   | 0.642   |
| INR                                            | 1.02 (0.97, 1.08)   | 1.02 (0.98, 1.10)| 1.02 (0.97, 1.07)   | 0.719   |
| Fibrinogen (g/L)                               | 3.61 (3.09, 4.28)   | 3.50 (2.98, 4.15)| 3.64 (3.15, 4.30)   | 0.046   |
| **Comorbidities**                              |                     |                 |                      |         |
| Hypertension, n (%)                            | 252 (38.6%)         | 40 (41.7%)      | 212 (38.1%)          | 0.503   |
| Diabetes mellitus, n (%)                       | 77 (11.8%)          | 11 (11.5%)      | 66 (11.8%)           | 0.913   |
| Cardiovascular disease, n (%)                  | 42 (6.4%)           |                 | 36 (6.5%)           | 0.937   |
| **Medication use**                             |                     |                 |                      |         |
| Atorvastatin therapy, n (%)                    | 478 (73.2%)         | 74 (77.1%)      | 404 (72.5%)          | 0.352   |
| PAMBA therapy, n (%)                           | 189 (28.9%)         | 26 (27.1%)      | 163 (29.3%)          | 0.663   |
| **Hematoma location**                          |                     |                 |                      | 0.957   |
| Unilateral left, n (%)                         | 288 (44.1%)         | 42 (43.8%)      | 246 (44.2%)          |         |
| Unilateral right, n (%)                        | 216 (33.1%)         | 31 (32.3%)      | 185 (33.2%)          |         |
| Bilateral, n (%)                               | 149 (22.8%)         | 23 (24.0%)      | 126 (22.6%)          |         |
| **Postoperative bleeding**                     | 136 (20.8%)         | 22 (22.9%)      | 114 (20.5%)          | 0.585   |
| GOS at discharge                               | 5, n (%)            | 593 (90.8%)     | 503 (90.3%)          | 0.549   |
|                                               | 4, n (%)            | 48 (7.4%)       | 43 (7.7%)            |         |
|                                               | 3, n (%)            | 12 (1.8%)       | 11 (2.0%)            |         |
| **Preoperative investigation**                 |                     |                 |                      |         |
| N=632                                          |                     |                 |                      |         |
| BUN (mmol/L)                                   | 5.3 (4.4, 6.5)      | 5.9 (4.8, 6.9)  | 5.2 (4.3, 6.4)       | 0.001   |
NOTE. SBP, systolic blood pressure; DBP, diastolic blood pressure; Cr, creatinine; INR, international normalized ratio; PAMBA, para-aminomethylbenzoic acid; BUN, blood urea nitrogen; GOS, Glasgow Outcome Scale.

The descriptive characteristics between groups with and without recurrence are shown in Table 1, including the demographics, laboratory, imaging, medication and comorbidity characteristics. In this study, 96 (14.7%) cases were diagnosed as CSDH recurrence, including 16 patients who needed a second operation. Compared with non-recurrence, the cases in the group of recurrence were older and have lower levels of serum leukocyte, neutrophil and platelet count. However, lower serum fibrinogen concentration was examined in recurrence cases ($P<0.05$). Moreover, there was a statistical difference between pre and post-operative groups on serum BUN concentration ($P=0.001$ and $P<0.001$, respectively). Table 2 revealed that the BUN level of the pre-operative group was significantly higher than the post-operative BUN level in the non-recurrence group ($P<0.001$) while it showed no obvious difference in the recurrence group.

| Variable                  | Preoperative BUN (mmol/L) | Postoperative BUN (mmol/L) | $P$-value |
|---------------------------|---------------------------|-----------------------------|-----------|
| Total (n=632)             | 5.3 (4.4, 6.5)            | 4.9 (4.0, 6.4)              | $<0.001$  |
| Recurrence (n=95)         | 5.9 (4.8, 6.9)            | 5.85 (4.4, 6.9)             | 0.177     |
| Non-Recurrence (n=537)    | 5.2 (4.3, 6.4)            | 4.9 (3.9, 6.25)             | $<0.001$  |

BUN, blood urea nitrogen;

Baseline characteristics of all cases in BUN quartiles

For further exploration, the cases were divided into 4 groups based on quartiles of the postoperative BUN concentration. The cut-off points for this stratification of the BUN concentration into quartiles were: $Q1 \leq 4.0 \text{ mmol/L}$, $4.0 < Q2 \leq 4.9 \text{ mmol/L}$, $4.9 < Q3 \leq 6.4 \text{ mmol/L}$ and $Q4 > 6.4 \text{ mmol/L}$. Table 3 summarizes the characteristics of the CSDH cases by the quartiles of BUN. Cases with different postoperative BUN concentration appeared to be similar in most features except for age, Cr, erythrocyte and hemoglobin. These factors would be adjusted for multivariate-adjusted binary logistic regression for good measure. 22 (14%) of 157 patients in the highest quartile of BUN suffered moderate disability at discharge which was statistically higher than in other quartiles.

Table 3
Baseline Characteristics of Patients with Chronic Subdural Hematoma according to postoperative BUN quartile.
| Variables          | BUN quartiles | 1 quartile | 2 quartile | 3 quartile | 4 quartile | P | value |
|--------------------|---------------|------------|------------|------------|------------|---|-------|
|                    | n=170 | n=162 | n=164 | n=157 | | |
| **BUN (mmol/L)**   | 3.4 (3.0,3.7) | 4.5 (4.3,4.8) | 5.7 (5.3,6.0) | 7.4 (6.9,8.3) | | <0.001 |
| **Demographic**    |              |            |            |            |            |   |       |
| **parameters**     |              |            |            |            |            |   |       |
| Age (years)        | 68 (61,76) | 72 (63,79) | 73 (66,82) | 76 (69,83) | | <0.001 |
| Gender, male, n (%)| 140 (82.4%) | 148 (91.4%) | 141 (86.0%) | 132 (84.1%) | | 0.103 |
| Current drinking, n (%) | 61 (35.9%) | 62 (38.3%) | 58 (35.4%) | 53 (33.8%) | | 0.866 |
| Current smoking, n (%) | 68 (39.4%) | 56 (34.6%) | 63 (38.4%) | 51 (32.5%) | | 0.526 |
| Baseline SBP (mmHg) | 138.4 ± 19.4 | 139.3 ± 19.7 | 141.0 ± 20.6 | 142.5 ± 21.0 | | 0.274 |
| Baseline DBP (mmHg) | 79 (71,87) | 79 (73,86) | 77 (72,88) | 78 (71,87) | | 0.984 |
| **Laboratory**     |              |            |            |            |            |   |       |
| **investigation**  |              |            |            |            |            |   |       |
| Blood glucose (mmol/L) | 5.5 (4.8,6.5) | 5.6 (4.7,6.6) | 5.6 (4.7,6.8) | 5.4 (4.5,6.7) | | 0.818 |
| Cr (μmol/L)        | 60 (54,68) | 66 (57,75) | 69 (60,80) | 74 (63,87) | | <0.001 |
| Leukocyte (X10^9/L) | 7.00 | 6.14,8.45 | 6.97,5.81,8.62 | 6.98,5.73,8.33 | | 0.677 |
| Neutrophil (X10^9/L) | 4.78 | 3.84,6.31 | 4.68,3.76,6.30 | 4.52,3.59,5.92 | | 0.369 |
| Lymphocyte (X10^9/L) | 1.50,1.10,1.80 | 1.40,1.10,1.71 | 1.50,1.11,1.87 | 1.45,1.10,1.81 | | 0.518 |
| Erythrocyte (X10^12/L) | 4.30 ± 0.51 | 4.27 ± 0.50 | 4.24 ± 0.52 | 4.12 ± 0.52 | | 0.008 |
| Hemoglobin (g/L)   | 133 (120,144) | 133 (123,142) | 132 (120,144) | 130 (116,139) | | 0.047 |
| Platelet (X10^9/L) | 219 (174,259) | 206 (175,250) | 203 (175,243) | 201 (162,249) | | 0.183 |
| Prothrombin Time (s) | 13.3 (12.7,13.8) | 13.2 (12.9,13.9) | 13.4 (12.9,13.9) | 13.4 (12.9,14.1) | | 0.523 |
| INR                | 1.02 (0.97,1.07) | 1.02 (0.97,1.08) | 1.03 (0.97,1.08) | 1.03 (0.97,1.10) | | 0.484 |
| Fibrinogen (g/L)   | 3.55 (3.11,4.38) | 3.71 (3.10,4.35) | 3.61 (2.97,4.18) | 3.67 (3.12,4.26) | | 0.740 |
| **Comorbidities**  |              |            |            |            |            |   |       |
| Hypertension, n (%) | 61 (35.9%) | 61 (37.7%) | 60 (36.6%) | 70 (44.6%) | | 0.355 |
| Diabetes mellitus, n (%) | 18 (10.6%) | 18 (11.1%) | 17 (10.4%) | 24 (15.3%) | | 0.480 |
| Cardiovascular disease, n (%) | 9 (5.3%) | 10 (6.2%) | 11 (6.7%) | 12 (7.6%) | | 0.853 |
| **Medication use** |              |            |            |            |            |   |       |
| Atorvastatin therapy, n (%) | 124 (72.9%) | 118 (72.8%) | 114 (69.5%) | 122 (77.7%) | | 0.427 |
| PAMBA therapy, n (%) | 40 (23.5%) | 45 (27.8%) | 53 (32.3%) | 51 (32.5%) | | 0.222 |
| **Hematoma location** |              |            |            |            |            |   |       |
| Unilateral left, n (%) | 68 (40.0%) | 82 (50.6%) | 75 (45.7%) | 63 (40.1%) | | 0.367 |
| Unilateral right, n (%) | 62 (36.5%) | 48 (29.6%) | 55 (33.5%) | 51 (32.5%) | | 0.367 |
| Bilateral, n (%) | 40 (23.5%) | 32 (19.8%) | 34 (20.7%) | 43 (27.4%) | | 0.042 |
| **GOS at discharge** |              |            |            |            |            |   |       |
Association between the BUN concentrations and recurrence

Significant differences were observed between the recurrence and non-recurrence groups in BUN concentration quartiles of cases ($P=0.003$). The proportion of cases in the lowest quartile ($\leq 4.0$ mmol/L) was dramatically low in the recurrence group ($P=0.027$), whilst the proportion of cases in the highest quartile ($>6.4$ mmol/L) was significantly high in the recurrence group ($P=0.012$) (Table 4).

Table 4
BUN quartiles of patients.

| Variable | Recurrence (n=96) | Non-Recurrence (n=557) | $\chi^2$ | $P$-value |
|----------|-------------------|------------------------|---------|-----------|
| BUN (mmol/L) | | | | |
| Quartile 1 ($\leq 4.0$) | 14 (14.6%) | 156 (28.0%) | 4.870 | 0.027 |
| Quartile 2 ($>4.0, \leq 4.9$) | 22 (22.9%) | 140 (25.1%) | 0.132 | 0.717 |
| Quartile 3 ($>4.9, \leq 6.4$) | 24 (25.0%) | 140 (25.1%) | 0.000 | 0.983 |
| Quartile 4 ($>6.4$) | 36 (37.5%) | 121 (21.7%) | 6.283 | 0.012 |

BUN, blood urea nitrogen;

In Table 5, with all cases taken as a whole, the condition that CSDH recurrence was interpreted as a dependent variable and the lowest quartile was interpreted as the reference was used for postoperative BUN level in the binary logistic regression models. The highest quartile of BUN concentration ($>6.4$ mmol/L) was independently estimated as a risk factor of CSDH recurrence with an unadjusted OR of 3.315 (95% CI: 1.711–6.423, $P<0.001$). After adjusting for the confounders including sex, age, current alcohol drinking, current smoking, comorbidities (hypertension, diabetes mellitus, coronary heart disease), medicine (Atorvastatin and PAMBA), and laboratory investigation (platelet, fibrinogen, leukocyte, erythrocyte, hemoglobin, Cr), the highest quartile of BUN remained significantly and independently associated with CSDH recurrence (model 1: OR=2.892, 95% CI: 1.463–5.717, $P=0.002$; model 2: OR=2.939, 95% CI: 1.480–5.836, $P=0.002$; model 3: OR=3.069, 95% CI: 1.488–6.330, $P=0.002$). There was no multicollinearity between the independent variables in model 3. Furthermore, restricted cubic spline regressions were used to explore the linear relationship between BUN concentration and the risk of CSDH recurrence (Figure 3). Most importantly, it could be observed visually that the highest quartile had a significantly high OR value.

Table 5
Multivariate adjusted odds ratios for the association between BUN levels and Recurrence.

| Quartile | OR<sup>a</sup> | 95%CI          | P-value |
|----------|---------------|----------------|---------|
| Unadjusted |               |                |         |
| Middle   | 1.751         | 0.863-3.554    | 0.121   |
| Higher   | 1.910         | 0.951-3.837    | 0.069   |
| Highest  | 3.315         | 1.711-6.423    | <0.001  |
| Model 1<sup>b</sup> |           |                |         |
| Middle   | 1.590         | 0.778-3.252    | 0.204   |
| Higher   | 1.713         | 0.842-3.483    | 0.137   |
| Highest  | 2.892         | 1.463-5.717    | 0.002   |
| Model 2<sup>c</sup> |           |                |         |
| Middle   | 1.612         | 0.788-3.299    | 0.191   |
| Higher   | 1.768         | 0.866-3.611    | 0.118   |
| Highest  | 2.939         | 1.480-5.836    | 0.002   |
| Model 3<sup>d</sup> |           |                |         |
| Middle   | 1.612         | 0.780-3.333    | 0.197   |
| Higher   | 1.733         | 0.837-3.590    | 0.139   |
| Highest  | 3.069         | 1.488-6.330    | 0.002   |

OR, odds ratio; CI confidence level; Cr, creatinine; Recurrence of postoperative CSDH.

<sup>a</sup> Reference OR (1.000) is the lowest quartile of BUN for Recurrence of CSDH.

<sup>b</sup> Model 1: adjusted for age, sex, current smoking, current alcohol drinking.

<sup>c</sup> Model 2: adjusted for covariates from Model 1 and further adjusted for medical history (coronary heart disease, diabetes mellitus, hypertension) and medicine (Atorvastatin and PAMBA)

<sup>d</sup> Model 3: adjusted for covariates from Model 2 and further adjusted for Platelet, Fibrinogen, Leukocyte, Erythrocyte, Hemoglobin, Cr.

**Discussion**

To the best of our knowledge, this is the first study to investigate the association between BUN concentration and the recurrence of CSDH after evacuation. Our results indicated that high postoperative BUN concentration was related to the prevalence of CSDH recurrence within 3 months after the operation. Our findings hence suggest that the postoperative BUN concentration could be an available risk factor for CSDH recurrence.

BUN is a waste product of protein catabolism which is linked with poor prognosis and mortality in acute or chronic heart failure[12]. In addition, a study of 3355 AIS patients by You et al observed that higher BUN had a 3.75-fold higher risk of in-hospital mortality[11]. In the present study, we found that patients with a relatively higher level of BUN were more likely to be moderately disabled at discharge. This was consistent with the previous studies that elevated BUN levels during hospitalization was related to a poor outcome. However, little data was found on the relationship between BUN and recurrence of CSDH. In this study, we observed that cases with a higher BUN level presented a trend toward a higher recurrence rate of CSDH. Furthermore, elevated BUN was associated with an enhanced risk of CSDH recurrence and cases with the highest postoperative BUN (>6.4 mmol/L) seemed to have a 3.069-fold increase in danger of CSDH recurrence after adjusting for the potential confounders. The normal range of BUN level in the
research hospital is 2.8-7.2 mmol/L which means the majority of patients presented with BUN level in the normal range. The BUN levels reflected not only the renal function but also other reactions that were mentioned below. In this study, the Cr level did not have an effect on the recurrence of CSDH which means there was no direct association between renal function and CSDH recurrence. The cutoff value of the postoperative BUN level in this study is 6.4 mmol/L and it indicated that the normal range of BUN level for intracranial lesion might be different from the systematic level. Also, elevated preoperative BUN levels showed an association with the recurrence of CSDH after logistic regression (See Supplemental Table, Additional File 1). Comparison between pre and post-operative BUN levels revealed that the BUN in the non-recurrence group significantly decreased after evacuation while it did not occur in the recurrence group, further confirming the relationship between BUN and CSDH recurrence.

The precise mechanisms underlying the association between elevated BUN and CSDH recurrence remained unclear. A potential explanation for this might be that a systemic increase in serum BUN induces intracranial multiple responses, which in turn can produce hematoma expansion and bring out CSDH recurrence. Some studies have revealed that the predictive value of BUN may be induced by its connection with other variables, such as protein intake, protein catabolism, nitrogen production and neurohormonal activation[12, 13]. On the other hand, CSDH was recently suggested to be formed through complex processes including angiogenesis, fibrinolysis and inflammation[14], and the recurrence of CSDH follows the same process as formation. There is strong evidence to show that vascular endothelial growth factor (VEGF) was related to the generation and steady increase of CSDH fluid volume[15-17] as well as the risk of CSDH recurrence[18]. Interestingly, Lin et al observed that VEGF expression was positively correlated with BUN[19]. Hence, these discoveries might explain the relatively good correlation between elevated BUN and CSDH recurrence.

Compared with CSDH cases without recurrence, our result also showed that CSDH cases with recurrence had significantly higher age, which is consistent with the reports of previous studies[7, 20]. However, we found that the older cases were associated with higher BUN and the difference of patient age was not statistically significant after multivariate logistic regression analysis though age affects the recurrence of CSDH through the change of BUN.

Additionally, decreased fibrinogen level was found to be associated with the CSDH recurrence. In fact, fibrinogen has been proven to be a potentially available risk factor for postoperative intracranial bleeding[21, 22] considering that elevating serum fibrinogen was targeted as a valid therapy for intracranial hemorrhage[23]. Moreover, high levels of fibrinogen degradation products (FDPs) have been examined in CSDH fluid[24, 25] and fresh red cells were identified within CSDH fluid[24], suggesting that bleeding is an essential part of CSDH formation. The current study did not reveal a significant difference between postoperative atorvastatin use and CSDH recurrence. This finding runs contrary to existing studies[26, 27], hence, making the relationship between atorvastatin administration and CSDH recurrence puzzling.
There were a few limitations recognized in the present study. First, this study is a retrospective study and the selection bias is inevitable. Secondly, this is only a single-center clinical finding, which may impact the generalization of the results, thus further prospective research with plenty of patients might be required. Finally, considering that the role BUN plays in the CSDH recurrence is still confusing, more studies need to be pursued to further and better delineate CSDH formation in the future.

**Conclusion**

The most obvious finding from this study was that elevated BUN at post-operation was independently associated with the recurrence of CSDH. The result suggested that a high level of postoperative BUN might serve as a risk factor of CSDH recurrence, so the determination of serum BUN after evacuation is important for patients with CSDH. Further prospective studies need to be undertaken to validate the causal relationship between BUN and CSDH recurrence.

**Abbreviations**

CSDH: chronic subdural hematoma; BUN: Blood Urea Nitrogen; BHI: burr-hole irrigation; GCS: Glasgow coma score; CT: computed tomography; MRI: magnetic resonance imaging; AIS: acute ischemic stroke; GOS: Glasgow Outcome Scale; ANOVA: analysis of variance; OR: odds ratio; CI: confidence interval; Cr: creatinine; PAMBA: para-aminomethylbenzoic acid; SBP: systolic blood pressure; DBP: diastolic blood pressure; INR: international normalized ratio; VEGF: vascular endothelial growth factor; FDPs: fibrinogen degradation products.

**Declarations**

**Ethical approval and consent to participate**

The ethics committee of Wenzhou Medical University First Affiliated Hospital ruled that no formal ethics approval was required in this retrospective study and determined that informed consent was not required.

**Consent to publish**

Not applicable.

**Availability of data and materials**

The datasets used and analyzed during the current study are available in supported additional file 2 and the confidential patient data was erased.

**Competing interests**

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership,
employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (No. 81771262), Zhejiang Health Science and Technology Project (2016RCA022), Zhejiang Provincial Natural Science Foundation of China (LQ20H090005) and Wenzhou Municipal Science and Technology Bureau Project of China (Y20190568).

**Authors’ contributions**

NW, JH and AO wrote the manuscript. NW performed the statistical analyses. NW, XZ and YL gathered the data and are responsible for the integrity of registered data. LR, JY and QZ designed and coordinated the study. SY contributed to the analysis and interpretation of data. All authors read and approved the submitted version.

**Acknowledgments**

Not applicable.

**Author details**

1. Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;
2. Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China;
3. Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA

**References**

1. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Andersen KN, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35:2:155-69; discussion 69; doi: 10.1007/s10143-011-0349-y.
2. Rauhala M, Luoto TM, Huhtala H, Iverson GL, Niskakangas T, Ohman J, et al. The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. J Neurosurg. 2019:1-11; doi: 10.3171/2018.12.JNS183035.
3. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol. 2014;10 10:570-8; doi: 10.1038/nrneurol.2014.163.
4. You CG, Zheng XS. Postoperative pneumocephalus increases the recurrence rate of chronic subdural hematoma. Clin Neurol Neurosurg. 2018;166:56-60; doi: 10.1016/j.clineuro.2018.01.029.

5. Wang Y, Zhou J, Fan C, Wang D, Jiao F, Liu B, et al. Influence of antithrombotic agents on the recurrence of chronic subdural hematomas and the quest about the recommencement of antithrombotic agents: A meta-analysis. J Clin Neurosci. 2017;38:79-83; doi: 10.1016/j.jocn.2016.12.001.

6. Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13 8:823-7; doi: 10.1016/j.jocn.2004.12.013.

7. Leroy HA, Aboukais R, Reyns N, Bourgeois P, Labreuche J, Duhamel A, et al. Predictors of functional outcomes and recurrence of chronic subdural hematomas. J Clin Neurosci. 2015;22 12:1895-900; doi: 10.1016/j.jocn.2015.03.064.

8. Schrock JW, Glasenapp M, Drogell K. Elevated blood urea nitrogen/creatinine ratio is associated with poor outcome in patients with ischemic stroke. Clin Neurol Neurosurg. 2012;114 7:881-4; doi: 10.1016/j.clineuro.2012.01.031.

9. Lin CJ, Yang JT, Huang YC, Tsai YH, Lee MH, Lee M, et al. Favorable outcome of blood urea nitrogen/creatinine-based hydration therapy 3 months after acute ischemic stroke. Am J Emerg Med. 2016;34 12:2414-8; doi: 10.1016/j.ajem.2016.09.033.

10. Deng L, Wang C, Qiu S, Bian H, Wang L, Li Y, et al. Association between Blood Urea Nitrogen-to-creatinine Ratio and Three-Month Outcome in Patients with Acute Ischemic Stroke. Curr Neurovasc Res. 2019;16 2:166-72; doi: 10.2174/1567202616666190412123705.

11. You S, Zheng D, Zhong C, Wang X, Tang W, Sheng L, et al. Prognostic Significance of Blood Urea Nitrogen in Acute Ischemic Stroke. Circ J. 2018;82 2:572-8; doi: 10.1253/circj.CJ-17-0485.

12. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Current and novel renal biomarkers in heart failure. Heart Fail Rev. 2012;17 2:241-50; doi: 10.1007/s10741-011-9254-2.

13. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 2008;1 1:2-5; doi: 10.1161/CIRCHEARTFAILURE.108.770834.

14. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017;14 1:108; doi: 10.1186/s12974-017-0881-y.

15. Weigel R, Hohenstein A, Schilling L. Vascular endothelial growth factor concentration in chronic subdural hematoma fluid is related to computed tomography appearance and exudation rate. J Neurotrauma. 2014;31 7:670-3; doi: 10.1089/neu.2013.2884.

16. Shono T, Inamura T, Morioka T, Matsumoto K, Suzuki SO, Ikezaki K, et al. Vascular endothelial growth factor in chronic subdural haematomas. J Clin Neurosci. 2001;8 5:411-5; doi: 10.1054/jocn.2000.0951.

17. Hua C, Zhao G, Feng Y, Yuan H, Song H, Bie L. Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma. J Neurotrauma. 2016;33 1:65-70; doi: 10.1089/neu.2014.3724.
18. Hong HJ, Kim YJ, Yi HJ, Ko Y, Oh SJ, Kim JM. Role of angiogenic growth factors and inflammatory cytokine on recurrence of chronic subdural hematoma. Surg Neurol. 2009;71 2:161-5; discussion 5-6; doi: 10.1016/j.surneu.2008.01.023.

19. Lin S, Teng J, Li J, Sun F, Yuan D, Chang J. Association of Chemerin and Vascular Endothelial Growth Factor (VEGF) with Diabetic Nephropathy. Med Sci Monit. 2016;22:3209-14; doi:10.12659/msm.896781.

20. Motoie R, Karashima S, Otsuji R, Ren N, Nagaoka S, Maeda K, et al. Recurrence in 787 Patients with Chronic Subdural Hematoma: Retrospective Cohort Investigation of Associated Factors Including Direct Oral Anticoagulant Use. World Neurosurg. 2018;118:e87-e91; doi:10.1016/j.wneu.2018.06.124.

21. Zhang XH, Wang QM, Chen H, Chen YH, Han W, Wang FR, et al. Clinical characteristics and risk factors of intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95 10:1637-43; doi: 10.1007/s00277-016-2767-y.

22. Adelmann D, Klaus DA, Illievich UM, Krenn CG, Krall C, Kozek-Langenecker S, et al. Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy. Br J Anaesth. 2014;113 4:628-33; doi: 10.1093/bja/aeu133.

23. McBride D, Tang J, Zhang JH. Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage. Curr Drug Targets. 2017;18 12:1349-57; doi:10.2174/1389450117666151209123857.

24. Ito H, Yamamoto S, Komai T, Mizukoshi H. Role of local hyperfibrinolysis in the etiology of chronic subdural hematoma. Journal of neurosurgery. 1976;45 1:26-31; doi: 10.3171/jns.1976.45.1.0026.

25. Heula AL, Ohlmeier S, Sajanti J, Majamaa K. Characterization of chronic subdural hematoma fluid proteome. Neurosurgery. 2013;73 2:317-31; doi: 10.1227/01.neu.0000430323.24623.de.

26. Tang R, Shi J, Li X, Zou Y, Wang L, Chen Y, et al. Effects of Atorvastatin on Surgical Treatments of Chronic Subdural Hematoma. World Neurosurg. 2018;117:e425-e9; doi: 10.1016/j.wneu.2018.06.047.

27. Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized Clinical Trial. JAMA Neurol. 2018;75 11:1338-46; doi: 10.1001/jamaneurol.2018.2030.

**Supplemental Table**

**Supplemental table**
Multivariate adjusted odds ratios for the association between preoperative BUN and Recurrence.

| Variables                  | ORa   | 95%CI             | P-value   |
|----------------------------|-------|-------------------|-----------|
| Preoperative BUN (mmol/L)b  |       |                   | <0.001    |
| Quartile 2                 | 7.266 | 1.597-32.698      | 0.010     |
| Quartile 3                 | 10.845| 2.407-48.854      | 0.002     |
| Quartile 4                 | 49.595| 11.624-211.609    | <0.001    |

BUN, blood urea nitrogen; OR, odds ratio; CI confidence level.
a Reference OR (1.000) is the lowest quartile of preoperative BUN for Recurrence of CSDH.
b Adjusted for the same variables as model 2 in table 5.